BRPI0506807A - método de gerenciamento de consumo de alimento e composição farmacológica - Google Patents

método de gerenciamento de consumo de alimento e composição farmacológica

Info

Publication number
BRPI0506807A
BRPI0506807A BRPI0506807-0A BRPI0506807A BRPI0506807A BR PI0506807 A BRPI0506807 A BR PI0506807A BR PI0506807 A BRPI0506807 A BR PI0506807A BR PI0506807 A BRPI0506807 A BR PI0506807A
Authority
BR
Brazil
Prior art keywords
food consumption
eating
consumption management
pharmacological composition
management method
Prior art date
Application number
BRPI0506807-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Nir Barak
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL16159504A external-priority patent/IL161595A0/xx
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Publication of BRPI0506807A publication Critical patent/BRPI0506807A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0506807-0A 2004-04-22 2005-04-21 método de gerenciamento de consumo de alimento e composição farmacológica BRPI0506807A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16159504A IL161595A0 (en) 2004-04-22 2004-04-22 Betahistine as a weight management agent
US67029005P 2005-04-12 2005-04-12
PCT/IL2005/000440 WO2005101979A2 (en) 2004-04-22 2005-04-21 Method of food intake management

Publications (1)

Publication Number Publication Date
BRPI0506807A true BRPI0506807A (pt) 2007-05-29

Family

ID=35197421

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506807-0A BRPI0506807A (pt) 2004-04-22 2005-04-21 método de gerenciamento de consumo de alimento e composição farmacológica

Country Status (10)

Country Link
US (5) US7737165B2 (https=)
EP (1) EP1737454A4 (https=)
JP (1) JP2007533733A (https=)
KR (1) KR20060134041A (https=)
BR (1) BRPI0506807A (https=)
CA (1) CA2553309A1 (https=)
EA (1) EA200601414A1 (https=)
IL (1) IL176793A0 (https=)
NO (1) NO20063221L (https=)
WO (1) WO2005101979A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
UA98938C2 (ru) * 2006-06-16 2012-07-10 Теракос, Инк. Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
JP5513378B2 (ja) * 2007-06-15 2014-06-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 治療化合物
KR101621726B1 (ko) 2008-05-27 2016-05-17 더 유니버시티 오브 멜버른 유스타키오관 기능장애 치료용 국소 약학적 조성물
US20120115778A1 (en) * 2009-07-15 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2
US20110021507A1 (en) * 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
JP2013507713A (ja) * 2009-10-13 2013-03-04 ネステク ソシエテ アノニム 食物摂取を評定するシステム及びそのシステムを使用する方法
TR201908514T4 (tr) 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
US20110143704A1 (en) 2009-12-14 2011-06-16 William Lorentz Specialized dial a chip
US8778960B2 (en) * 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
RU2540911C2 (ru) * 2013-06-11 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами
DE102015202695A1 (de) * 2015-02-13 2016-08-18 Carl Zeiss Smt Gmbh Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels
ES2969301T3 (es) * 2017-02-02 2024-05-17 Otolanum Ag Composición intranasal que comprende betahistina
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR20250154480A (ko) * 2023-02-28 2025-10-28 바이오하벤 테라퓨틱스 리미티드 강박 관련 장애, 틱 장애 및 글루타메이트 흥분독성 관련 장애의 치료 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577871A (en) * 1976-05-28 1980-10-29 Unimed Inc Prevention of myocardial infarction
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69939027D1 (de) * 1998-12-23 2008-08-14 Maxim Pharm Inc Synthese von histamin-dihydrochlorid
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
IT1309591B1 (it) 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
WO2000071106A2 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treating weight gain
WO2001066081A2 (de) * 2000-03-08 2001-09-13 Awd.Pharma Gmbh & Co.Kg Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
WO2002087556A2 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
AU2003266165A1 (en) 2002-09-13 2004-04-30 Hossein Dovlatabadi Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline

Also Published As

Publication number Publication date
US20080004322A1 (en) 2008-01-03
WO2005101979A3 (en) 2006-07-27
WO2005101979A2 (en) 2005-11-03
EP1737454A2 (en) 2007-01-03
US20060073217A1 (en) 2006-04-06
CA2553309A1 (en) 2005-11-03
US7737165B2 (en) 2010-06-15
US20080004324A1 (en) 2008-01-03
EP1737454A4 (en) 2007-08-08
US20060084686A1 (en) 2006-04-20
IL176793A0 (en) 2006-10-31
JP2007533733A (ja) 2007-11-22
NO20063221L (no) 2006-10-06
US20080051439A1 (en) 2008-02-28
KR20060134041A (ko) 2006-12-27
EA200601414A1 (ru) 2007-02-27

Similar Documents

Publication Publication Date Title
BRPI0506807A (pt) método de gerenciamento de consumo de alimento e composição farmacológica
Hawkley et al. Loneliness matters: A theoretical and empirical review of consequences and mechanisms
Azin et al. Body contouring surgery after bariatric surgery: a study of cost as a barrier and impact on psychological well-being
EA200900626A1 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
CL2008002227A1 (es) Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad.
BR112013018782A2 (pt) compostos e seus efeitos no comportamento alimentar
BRPI0517932A8 (pt) Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma
Griffin et al. Higher protein diet for weight management in young overweight women: a 12‐month randomized controlled trial
Ocobock Human cold adaptation: An unfinished agenda v2. 0
Villa‐Rodriguez et al. German Chamomile (Matricaria chamomilla) Extract and Its Major Polyphenols Inhibit Intestinal α‐glycosidases in vitro
Behera et al. Probiotics ameliorate gut‐microbial dysbiosis, intestinal permeability, systemic inflammation, and skeletal muscle dysfunction in cystathionine‐β‐synthase‐deficient mice
Salisa et al. Unmasking cAMP signalling in adipocytes
Mamidanna et al. Comparison of Parathyroid Hormone (PTH)(1‐34) and PTH (7‐34) Effects on Cell Signaling and Proliferation in Saos‐2 Osteoblast‐like Cells
Palmer et al. To Snack or Not to Snack: What should we advise for weight management?
Verma et al. 3189–ELEVATED CLONAL HEMATOPOIESIS SEEN IN WTC 9/11 FIRST RESPONDERS HAS DISTINCT AGE-RELATED PATTERNS AND RELIES ON IL1RAP FOR CLONAL EXPANSION
Gale et al. (131) Impact of an interactive music app on pain threshold, temporal summation, and conditioned pain modulation in healthy volunteers
Bentley De Novo Melatonin Synthesis in the Brain
Partinen et al. Sleep difficulties in Parkinson’s disease
Ezenwa et al. (132) Predictors of Opioid Analgesic Prescription in Adult Outpatients with Sickle Cell Disease
Gardner et al. Acceptability of pharmacist prescribed hormonal contraceptives for healthy women in the direct access study
Lee et al. IL‐4 induces interleukin‐6 (IL‐6) expression in human aortic endothelial cells
Lattimore et al. Effects of food intake and food cue exposure on body and weight satisfaction: The moderating role of body mass index (BMI) and dietary restraint
Paciotti et al. Effect of Curcumin on the Production of Interleukin‐6 from MDA‐MB‐231 Breast Cancer Cells
Bosworth et al. Effects of product labelling on eating topography, satiation and satiety
Lee et al. Cost-Benefit Analysis of Primary Prophylaxis with Granulocyte Colony Stimulating Factor (GCSF) in Reducing Hospital Admissions with Febrile Neutropenia in Patients Undergoing High Dose Chemotherapy for Non-Hodgkin Lymphoma (NHL).

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.